Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Don't loose sight of ...100s of companies now re-engaging

Don't loose sight of ...100s of companies now re-engaging

posted on Oct 21, 2009 10:23AM

CUPERTINO, Calif. – October 5, 2009 – Alliacense announced today a wave of new MMP™ Portfolio licensees less than three weeks after the USPTO announced it's decision to affirm the validity of US’336, the most widely recognized patent in the MMP Portfolio. The new licensees include Harman International, TPV Technology, and Textron Inc., and will result in both upfront and future payments, as the increasing rates of the MMP Licensing Program has made onetime, lump-sum licenses too expensive for some companies.

The agreements come on the heels of a string of successes in the reexamination of the MMP Portfolio™ patents by the USPTO and German Patent Court. In the past 9 months, the German Patent Court affirmed the validity of EP’730, and the USPTO has affirmed the validity of both US’584 and most recently US’336.

Despite the risk of willful infringement in cases where companies delay licensing decisions on the basis of reexams, hundreds of companies have been awaiting the outcome of US’336 and are now reengaging in licensing discussions in light of the escalating royalty rate structure of the MMP Portfolio™ Licensing Program.

Share
New Message
Please login to post a reply